COMPARATIVE ANALYSIS OF SOLUBLE OF CD40 LIGAND LEVELS IN HEART RECIPIENTS TREATED WITH CYCLOSPORINE A AND TACROLIMUS
https://doi.org/10.15825/1995-1191-2012-2-20-24
Abstract
Soluble form of CD40L is platelet activating factor, which is a marker of inflammation and thrombosis. Elevated levels of sCD40L before the heart transplantation are associated with the risk of early development of cardiova- scular complications.
The study included 54 patients who had received heart transplants. All recipients received a triple heart immu- nosuppressive therapy, including methylprednisolone, mycophenolate mofetil and cyclosporine A (20 recipients) or methylprednisolone, mycophenolate mofetil and tacrolimus (34 recipients). Patients were not differed by age, gender, etiology of heart failure before heart transplantation (p > 0,05). In the first group of transplant recipients, the relative risk of cardiovascular events with high sCD40L levels before transplantation was 3 2 (95% CI 1,4; 12,0). In the second group of recipients, respectively, 2.69 (95% CI 1,1; 8,5). SCD40L level after heart transplan- tation was significantly higher for patients receiving cyclosporine (P < 0.05).
Increasing concentrations of sCD40L are associated with a higher incidence of cardiovascular complications.
About the Authors
O. P. Shevchenko
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
T. A. Khalilulin
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
O. V. Orlova
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
E. N. Kazakov
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
A. J. Kormer
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
V. V. Сhestukhin
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
B. L. Mironkov
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
References
1. Иммуносупрессия при трансплантации солидных органов / Под ред. С.В. Готье. М.–Тверь: Триада, 2011. 470 с.
2. Шевченко О.П., Природова О.Ф., Шевченко А.О., Орлова О.В. Уровень в крови лиганда CD40 – актив- ность сосудистого воспаления и отдаленный прогноз у больных ишемической болезнью сердца // Кардио- васкулярная терапия и профилактика. 2008. No 7 (1). С. 39–45.
3. Шевченко О.П., Орлова О.В., Казаков Э.Н. и др. Кли- ническое значение растворимого лиганда CD40 у реципиентов сердца // Вестник трансплантологии и искусственных органов. 2009. No 1. С. 40–45.
4. Balla J., Magyar M., Bereczki D. et al. Serum levels of released CD40L are increased in early onset occlusive co- ronary artery disease // Disease Markers. 2006. Vol. 22. P. 133–140.
5. Garlichs C.D., Eskafi S., Raaz D. et al. Patients with acu- te coronary syndromes express enhanced CD40 ligand/ CD154 on platelets // Heart. 2001. Vol. 86. P. 649–655.
6. Heeschen C., Dimmeler S., Hamm C.W. et al. Soluble CD40 ligand in acute coronary syndromes // N. Engl. J. Med. 2003. Vol. 348. P. 1104–1111.
7. Johnson M.R., Meyer K.H., Haft J. et al. Heart transplan- tation in the United States, 1999–2008 // Am. J. Trans- plant. 2010. Vol. 10 (4 part 2). P. 1035–1046.
8. De Lemos J.A., Zirlik A., Schonbeck U. et al. Associa- tions between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis. Results from the Dallas Heart Study // Arterioscler. Thromb. Vasc. Biol. 2005. Vol. 25. P. 2192–2196.
9. Schonbeck U., Libby P. CD40 signaling and plaque insta- bility // Circ. Res. 2001. Vol. 89. P. 1092–1103.
10. Sipahi I., Starling R.C. Cardiac allograft vasculopathy: an update // Heart. Fail. Clin. 2007. Vol. 3. P. 87–95.
11. Valantine H. Cardiac allograft vasculopathy after heart
12. transplantation: risk factors and management // J. Heart.
13. Lung. Transplant. 2004. Vol. 23. P. 187–193.
14. Verbinnen B., Billiau A.D., Vermeiren J. et al. Contribu- tion of regulatory T cells and effector T cell deletion in tolerance induction by costimulation blockade // J. Im-
15. munol. 2008. Vol. 181. P. 1034–1042.
16. Varo N., de Lemos J.A., Libby P. et al. Soluble CD40L:
17. risk prediction after acute coronary syndromes // Circu-
18. lation. 2003. Vol. 108. P. 1049–1052.
19. Zarkhin V., Sarwal M.M. Microarrays: monitoring for
20. transplant tolerance and mechanistic insights // Clin. Lab. Med. 2008. Vol. 28. P. 385–410.
Review
For citations:
Shevchenko O.P., Khalilulin T.A., Orlova O.V., Kazakov E.N., Kormer A.J., Сhestukhin V.V., Mironkov B.L. COMPARATIVE ANALYSIS OF SOLUBLE OF CD40 LIGAND LEVELS IN HEART RECIPIENTS TREATED WITH CYCLOSPORINE A AND TACROLIMUS. Russian Journal of Transplantology and Artificial Organs. 2012;14(2):20-24. (In Russ.) https://doi.org/10.15825/1995-1191-2012-2-20-24
Views:
818
Email this article 